 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
38 News |  |
- ||| stapuldencel-T (DCVAC/PCa) / Sotio
Clinical, P3 data, Journal: Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. (Pubmed Central) - Apr 26, 2022
P3
In this phase 3 randomized clinical trial, DCVAC/PCa combined with docetaxel plus prednisone and continued as maintenance treatment did not extend OS in patients with mCRPC and was well tolerated. ClinicalTrials.gov Identifier: NCT02111577.
- |||||| stapuldencel-T (DCVAC/PCa) / Sotio, prednisone / Generic mfg., docetaxel / Generic mfg.
Clinical: "In this phase 3 randomized clinical trial, #DCVAC/PCa combined with #docetaxel plus prednisone & continued as maintenance treatment did not extend OS in patients with #mCRPC & was well tolerated" #ProstateCancer #immunotherapy https://t.co/gHFO02FViy (Twitter) - Feb 11, 2022
- | stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Jan 31, 2021
P1/2, N=5, Terminated, Sponsor: Sotio a.s.
ClinicalTrials.gov Identifier: NCT02111577. N=15 --> 5 | Trial completion date: Dec 2021 --> Jan 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Jan 2021; insufficient accrual
- | stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion date, Trial primary completion date, Metastases: A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Nov 5, 2020
P1/2, N=15, Recruiting, Sponsor: Sotio a.s.
N=15 --> 5 | Trial completion date: Dec 2021 --> Jan 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Jan 2021; insufficient accrual Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Apr 2020 --> Dec 2021
- ||||||| stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion, Trial completion date, Metastases: VIABLE: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 23, 2020
P3, N=1170, Completed, Sponsor: Sotio a.s.
Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Apr 2020 --> Dec 2021 Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Jan 2020
- | stapuldencel-T (DCVAC/PCa) / Sotio
Clinical, Review, Journal: Emerging therapeutic targets for patients with advanced prostate cancer. (Pubmed Central) - Jun 28, 2019
This wide spectrum of potential treatment strategies holds promise for additional improvements in the treatment of patients with CRPC, as these novel agents are aimed at targets known to be associated with growth and malignant progression of prostate cancer. If primary study endpoints are met, findings from ongoing phase III trials of well-tolerated and active combinations may provide new effective treatment options for advanced prostate cancer and thereby contribute to enhanced disease control in CRPC patients.
- |||| stapuldencel-T (DCVAC/PCa) / Sotio
Trial primary completion date, Metastases: VIABLE: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Feb 4, 2019
P3, N=1170, Active, not recruiting, Sponsor: Sotio a.s.
If primary study endpoints are met, findings from ongoing phase III trials of well-tolerated and active combinations may provide new effective treatment options for advanced prostate cancer and thereby contribute to enhanced disease control in CRPC patients. Trial primary completion date: Dec 2018 --> Dec 2019
- | stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion: Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer (clinicaltrials.gov) - Nov 15, 2018
P2, N=62, Completed, Sponsor: Sotio a.s.
Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- | stapuldencel-T (DCVAC/PCa) / Sotio
Trial primary completion date, Metastases: VIABLE: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Nov 7, 2018
P3, N=1170, Active, not recruiting, Sponsor: Sotio a.s.
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Dec 2018
- | stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion date, Trial primary completion date, Metastases: VIABLE: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Aug 14, 2018
P3, N=1170, Active, not recruiting, Sponsor: Sotio a.s.
Trial primary completion date: Oct 2017 --> Dec 2018 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Sep 2018 --> Oct 2017
- || stapuldencel-T (DCVAC/PCa) / Sotio
New P1/2 trial, Metastases: A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - May 1, 2018
P1/2, N=15, Recruiting, Sponsor: Sotio a.s.
- ||||| stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment closed, Metastases: VIABLE: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Oct 18, 2017
P3, N=1170, Active, not recruiting, Sponsor: Sotio a.s.
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Sep 2018 --> Oct 2017 Recruiting --> Active, not recruiting
- | stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion: Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=24, Completed, Sponsor: Sotio a.s.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion: Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=150, Completed, Sponsor: Sotio a.s.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion, Combination therapy, Metastases: ASN-002-IL: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=63, Completed, Sponsor: Sotio a.s.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion, P2 data, Metastases: Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=60, Completed, Sponsor: Sotio a.s.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| stapuldencel-T (DCVAC/PCa) / Sotio
Trial primary completion date, Metastases: VIABLE: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 25, 2017
P3, N=1170, Recruiting, Sponsor: Sotio a.s.
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Sep 2018
- || stapuldencel-T (DCVAC/PCa) / Sotio
Trial primary completion date, Combination therapy, Metastases: ASN-002-IL: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 17, 2016
P2, N=63, Active, not recruiting, Sponsor: Sotio a.s.
Trial primary completion date: Dec 2017 --> Sep 2018 Trial primary completion date: Oct 2013 --> Dec 2015
- stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment closed, Enrollment change, Trial primary completion date: Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer (clinicaltrials.gov) - Jul 1, 2015
P2, N=24, Active, not recruiting, Sponsor: Sotio a.s.
Trial primary completion date: Oct 2013 --> Dec 2015 Recruiting --> Active, not recruiting | N=75 --> 24 | Trial primary completion date: Mar 2016 --> Apr 2015
- stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment closed: Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer (clinicaltrials.gov) - Jul 1, 2015
P2, N=150, Active, not recruiting, Sponsor: Sotio a.s.
Recruiting --> Active, not recruiting | N=75 --> 24 | Trial primary completion date: Mar 2016 --> Apr 2015 Recruiting --> Active, not recruiting
- stapuldencel-T (DCVAC/PCa) / Sotio
Trial primary completion date: Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=150, Recruiting, Sponsor: Sotio a.s.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Jun 2015
- stapuldencel-T (DCVAC/PCa) / Sotio
Trial primary completion date: Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer (clinicaltrials.gov) - Dec 6, 2014
P2, N=75, Recruiting, Sponsor: Sotio a.s.
Trial primary completion date: Mar 2015 --> Jun 2015 Trial primary completion date: Dec 2015 --> Mar 2016
- stapuldencel-T (DCVAC/PCa) / Sotio
Trial primary completion date: Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer (clinicaltrials.gov) - Dec 6, 2014
P2, N=150, Recruiting, Sponsor: Sotio a.s.
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Dec 2014 --> Mar 2015
- | stapuldencel-T (DCVAC/PCa) / Sotio
New P2 trial: Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer (clinicaltrials.gov) - May 12, 2014
P2, N=75, Recruiting, Sponsor: Sotio a.s.
- stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment open: Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=150, Recruiting, Sponsor: Sotio a.s.
Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Recruiting
- stapuldencel-T (DCVAC/PCa) / Sotio
P2 data, Trial primary completion date, Metastases: Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=60, Active, not recruiting, Sponsor: Sotio a.s.
Active, not recruiting --> Recruiting Trial primary completion date: Apr 2014 --> May 2014
- stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment closed, P2 data, Metastases: Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=60, Active, not recruiting, Sponsor: Sotio a.s.
Trial primary completion date: Apr 2014 --> May 2014 Recruiting --> Active, not recruiting
- || stapuldencel-T (DCVAC/PCa) / Sotio
New P3 trial, Metastases: VIABLE: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 9, 2014
P3, N=1170, Recruiting, Sponsor: Sotio a.s.
- | stapuldencel-T (DCVAC/PCa) / Sotio
New P2 trial: Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer (clinicaltrials.gov) - Apr 6, 2014
P2, N=62, Active, not recruiting, Sponsor: Sotio a.s.
- | stapuldencel-T (DCVAC/PCa) / Sotio
New P2 trial: Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer (clinicaltrials.gov) - Apr 6, 2014
P2, N=150, Active, not recruiting, Sponsor: Sotio a.s.
- stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment closed: Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer (clinicaltrials.gov) - Apr 6, 2014
P2, N=62, Active, not recruiting, Sponsor: Sotio a.s.
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | stapuldencel-T (DCVAC/PCa) / Sotio
New P2 trial, Combination therapy, Metastases: ASN-002-IL: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer (clinicaltrials.gov) - Apr 6, 2014
P2, N=63, Active, not recruiting, Sponsor: Sotio a.s.
- stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment closed, Combination therapy, Metastases: ASN-002-IL: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer (clinicaltrials.gov) - Apr 6, 2014
P2, N=63, Active, not recruiting, Sponsor: Sotio a.s.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment closed: Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer (clinicaltrials.gov) - Apr 3, 2014
P2, N=150, Active, not recruiting, Sponsor: Sotio a.s.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | stapuldencel-T (DCVAC/PCa) / Sotio
New P2 trial, P2 data, Metastases: Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 3, 2014
P2, N=60, Recruiting, Sponsor: Sotio a.s.
- stapuldencel-T (DCVAC/PCa) / Sotio
Enrollment open, P2 data, Metastases: Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 1, 2014
P2, N=60, Recruiting, Sponsor: Sotio a.s.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting